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Targeted genome editing using engineered nuclease such as 
zinc-finger nucleases (ZFNs), transcription activator-like effector 
nucleases (TALENs) and clustered regularly interspaced short 
palindromic repeat (CRISPR)/CRISPR associated protein (Cas) systems 
have been used in cultured cells and whole organisms for functional 
study and therapeutic study. 
Despite broad interest in CRISPR/Cas9 mediated 
- iii -
genomengineering, off-target effects of entire genome have not been 
established. Therefore, development of methods to profiling 
genome-wide CRISPR/Cas9 off-target effects is the major challenge in 
this area. 
In this study, I characterize CRISPR/Cas9 off-target effect in 
clonal cells and bulk populations of cells. First I used Isaac variant 
calling program to analyze genome-wide indels in clonal cells. Second, 
I developed nuclease-digested genomes sequencing (digenome-seq) to 
profiling genome-wide CRISPR/Cas9 off-target effects in bulk 
populations. Using this methods, I validated off-target sites which indels 
were induced with frequencies below 0.1% and validated off-target 
effects can be avoided by replacing with modified sgRNAs. Third, I 
developed multiplex digenome-seq which can profiling more than ten 
sgRNA off-target effects in a one time. Based on multiplex 
digenome-seq result, I made a program for the choice of target sites 
and the off-target sites predictor respectively. 
Keywords : Genome engineering, Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR), CRISPR-associated protein (Cas), Whole 
genome sequencing (WGS)
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I. Introduction
Programmable endonucleases have been established as flexible 
tools for genome manipulation in cultured cells and whole organisms 
(Kim and Kim, 2014). These include zinc finger nucleases (ZFNs) 
(Bibikova et al., 2003; Kim et al., 2011; Kim et al., 2009; Porteus and 
Baltimore, 2003; Urnov et al., 2005), transcription activator-like effector 
nucleases (TALENs) (Kim et al., 2013a; Kim et al., 2013b; Miller et 
al., 2011), and RNA-guided engineered nucleases (RGENs) (Cho et al., 
2013; Cong et al., 2013; Hwang et al., 2013; Jiang et al., 2013; Jinek 
et al., 2013; Mali et al., 2013b) derived from the type II clustered 
regularly interspaced repeat (CRISPR)/CRISPR-associated (Cas) system. 
For the last several years, genome editing via programmable nucleases 
has been transforming almost every discipline in life science, 
biotechnology, and medicine. For example, targeted genetic 
modifications in stem and somatic cells are expected to pave the way 
for novel gene/cell therapy for the treatment of diverse genetic and 
acquired diseases (Park et al., 2014; Perez et al., 2008; Wu et al., 
2013). 
ZFNs consist of the zinc finger protein and DNA cutting 
restriction enzyme (FokI) (Kim et al. 1996; Bitinaite et al. 1998). The 
engineered nuclease induces double strand breaks (DSB) through FokI 
dimerization (Urnov et al. 2010). Like ZFNs, TALENs are also 
composed of the FokI nuclease, but the DNA binding domain is made 
up of transcription activator-like effectors (TALEs) derived from the 
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plant pathogen Xanthomonas spp. bacterium (Boch et al. 2009; Moscou 
and Bogdanove 2009). TALENs have greater success rates, higher 
average mutation rates, and lower cytotoxicity than ZFNs (Kim and 
Kim, 2014). 
CRISPR/Cas system is an adaptive prokaryotic adaptive immune 
system that destroys foreign DNA via three steps. First, fragmented 
foreign DNA is inserted into CRISPR array between repeat regions. 
Second, pre-crRNA is expressed in CRISPR locus, and is maturated to 
CRISPR RNA (crRNA) by RNase III. Third, maturated crRNA interacts 
with Cas9 protein for target degradation (Jinek et al., 2012). RGENs 
consist of the Cas9 endonuclease derived from S. pyogenes and single 
guide RNAs (sgRNAs) that recognize target DNA by Watson-Crick 
base pairing. This family of Cas9 proteins has two functional nuclease 
domains, RuvC and NHN. The RuvC domain binds to the non-target 
DNA strand, and the HNH nuclease domain cleaves the target DNA 
strand (Nishimasu et al., 2014). This protein recognizes a 5’-NGG-3’ 
protospacer-adjacent motif (PAM) sequence and forms a RNP complex 
with sgRNA. 
These programmable nucleases (ZFN, TALEN, and RGEN) 
produce site-specific DSBs in the genome, which greatly stimulates 
targeted mutagenesis and chromosomal rearrangements by homologous 
recombination (HR) in the presence of donor DNA, or nonhomologous 
end joining (NHEJ) in the absence of homology templates (Kim and 
Kim, 2014). Co-injection of a programmable endonuclease and a donor 
DNA template that contains homology sequences or single-strand 
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oligodeoxynucleotides (ssODN) produces a single codon change or DNA 
insertion via HR. Point mutations can be corrected or induced using the 
HR mechanism. Without donor DNA, DSBs induced small insertion and 
deletion (indel) or chromosomal rearrangements such as large deletions, 
duplications and inversions (Brunet et al., 2009; Cho et al., 2014; Lee 
et al., 2010; Lee et al., 2012). 
Unfortunately, recent studies demonstrate that RGENs produce 
several off-target effects. Recognition of 5’-NAG-3’ and 5’-NGA-3’ 
PAM or several mismatches between sgRNA and target DNA, 
especially in the PAM distal region, can induce mutations at that 
position (Cho et al., 2014; Cradick et al., 2013; Fu et al., 2013; Hsu et 
al., 2013; Lin et al., 2014; Pattanayak et al., 2013). To make matters 
worse RGENs can cleave off-target DNA sequences harboring an extra 
base (DNA bulge) or lacking a base (RNA bulge) compared to their 
respective sgRNA sequences (Lin et al., 2014). Off-target DNA 
cleavages can lead to mutations at unintended genomic loci such as 
proto-oncogenes and tumor suppressor genes, as well as gross 
chromosomal rearrangements such as translocations (Brunet et al., 2009; 
Cho et al., 2014), deletions (Lee et al., 2010), and inversions (Lee et 
al., 2012). These raise serious concerns about the use of programmable 
nucleases in research and medicine.
Several methods used to reduce off-target effects are studied as 
follows: sgRNAs with two extra guanine nucleotides at the 5’ end (Cho 
et al., 2014), truncated sgRNAs (Fu et al., 2014), paired Cas9 nickases 
(Cho et al., 2014; Mali et al., 2013a; Ran et al., 2013), a catalytically 
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dead Cas9 (dCas9)-FokI fusion (Guilinger et al., 2014; Tsai et al., 
2014), and purified Cas9/sgRNA complex delivery (Kim et al., 2014; 
Ramakrishna et al., 2014; Zuris et al., 2015). These different methods 
have been confirmed to reduced off-target effects in the homology 
sequence with on-target sequence. However off-target effects of entire 
genome have not been determined.
In the case of ZFN, off-target sites identification methods 
include systematic evolution of ligands by exponential amplification 
(SELEX) (Perez et al., 2008), integrase-deficient lentivirus (IDLV) 
capture in cells (Gabriel et al., 2011), and in vitro selection using a 
DNA substrate library for nuclease-mediated DNA cleavage (Pattanayak 
et al., 2011). But none of these methods are comprehensive enough to 
allow unbiased genome-wide analysis of nuclease specificity. For 
example, IDLV capture (Gabriel et al., 2011) and in vitro selection 
(Pattanayak et al., 2011) were independently used by two groups to 
examine the off-target effects of a CCR5-targeting ZFN, which has 
been under clinical trials for the treatment of HIV infection. 
Surprisingly, these two different methods captured entirely different sets 
of off-target sites in addition to the highly homologous CCR2 site that 
was already known to be an off-target site, highlighting the limitations 
of these methods. 
Off target sites for RGEN have been found with bioinformatic 
predictions based on sequence homology (Bae et al., 2014), mismatched 
guide RNA libraries (Hsu et al., 2013), in vitro selection (Pattanayak et 
al., 2013), reporter assays (Fu et al., 2013), and chromatin 
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immunoprecipitation coupled with deep sequencing (ChIP-Seq) (Kuscu et 
al., 2014; Wu et al., 2014). These studies demonstrate that RGENs 
have off-target effects, however, potential off-target sites have been 
computationally determined by homology sites. To address this critical 
issue in the field, it is imperative to develop methods that check the 
specificity of RGENs and other nucleases on a genomic scale in an 
unbiased manner.
In this study, I analyze genome-wide off-target effects of 
RGEN using whole genome sequencing (WGS) in clonal cells and in 
bulk populations of cells. First, I have subjected gene knockout clonal 
cells to WGS, and analyzed genome-wide indels using Isaac variant 
calling program. No off-target indels were found in these clonal cells. 
Second, I have developed nuclease-digested genomes sequencing 
(Digenome-seq) that profiles RGEN off-target effects in human 
population cells using one or several types of RGEN. Our results show 
that even ‘promiscuous’ RGENs are highly specific, inducing off-target 
mutations at only a handful, rather than hundreds or thousands, of sites 
in the entire genome. Based on Digenome-seq results I have finally 
developed a computer program to predict RGEN targetable sites which 
can minimize genome-wide off-target effects of CRISPR-Cas9.
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II. Materials and Methods
1. Cas9 and in vitro sgRNA
Recombinant Cas9 protein was purchased from ToolGen (South 
Korea). sgRNAs were synthesized by in vitro transcription using T7 
RNA polymerase as described previously (Kim et al., 2014). Briefly, 
sgRNA templates were generated by two complementary 
oligonucleotides which are quality-checked using MALDI-TOF 
(Macrogen) using annealing and extension. These templates were cloned 
by TA cloning (Enzynomics), and DNA template sequence was 
confirmed by capillary sequencing (Macrogen). sgRNA templates were 
incubated with T7 RNA polymerase in reaction buffer (40 mM 
Tris-HCl, 6 mM MgCl2, 10 mM DTT, 10 mM NaCl, 2 mM 
spermidine, NTP, and RNase inhibitor, pH 7.9) at 37℃ for 8 hr. 
Transcribed sgRNAs were pre-incubated with DNaseI to remove 
template DNA, and purified using PCR purification kits (Macrogen).
 2. Cell culture and transfection conditions
HAP1 cells were obtained from Haplogen and cultured in 
IMDM media supplemented with 10% FBS. HAP1 cells were 
co-transfected with the Cas9 expression plasmid, sgRNA-encoding 
plasmid, and the plasmid encoding the blasticidin resistance gene using 
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Fugene (Promega). Transfected cells were enriched by treatment with 
20ug/ml blasticidin. Single cell-derived gene knockout cells were 
obtained by limiting dilution. K562 cells were maintained in RPMI 
media supplemented with 10% FBS. K562 cells were electoporated with 
the Cas9 expression plasmid and sgRNA-encoding plasmid using 
Nucleofector (Lonza). HeLa cells were cultured in DMEM media 
supplemented with 10% FBS. HeLa cells (8x104) were co-transfected 
with the Cas9 expression plasmid (500ng) and the sgRNA -encoding 
plasmid (500ng) using lipofectamine 2000 (LifeTechnologies). Genomic 
DNA was isolated with the DNeasy Tissue kit (Qiagen) according to 
the manufacturer’s instructions after 48hr.
3. in vitro cleavage of genomic DNA
Genomic DNA was purified with the DNeasy Tissue kit 
(Qiagen) according to the manufacturer’s instructions. To digest target 
sequences in the genome, Cas9 protein (0.004ug to 40ug), which had 
been pre-incubated with sgRNA (0.003ug to 30ug) at room temperature 
for 10min, was mixed with genomic DNA (8ug) in a reaction volume 
of 400uL (100mM NaCl, 50mM Tris-HCl, 10mM MgCl2, and 100μg/ml 
BSA) and incubated at 37℃ for 8h. Digested genomic DNA was 
purified again with DNeasy Tissue kit (Qiagen), after RNase A 
(50ug/mL) was added to remove sgRNA. Purified digested genomic 
DNA was mixed with 2x SYBR Green Master Mix and analyzed by 
real-time quantitative PCR (qPCR). The percentage of target site 
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cleavage was measured using the △△CT method (Schmittgen and 
Livak, 2008).     
4. T7E1 assay
Genomic DNA was isolated using DNeasy Tissue kit (Qiagen) 
according to the manufacturer’s instructions. The target site was 
amplified by PCR. The T7E1 assay was performed as described 
previously (Kim et al., 2009). Briefly, amplified PCR products were 
denatured by heating and annealed slowly using a thermocycler. 
Annealed products were incubated with T7 endonuclease I (ToolGen) 
for 20 min at 37℃, and size-separated by agarose gel electrophoresis.   
  
5. Targeted deep sequencing
Genomic DNA segments spanning the on-target and potential 
off-target sites were amplified using Phusion polymerase (New England 
Biolabs). The resulting PCR amplicons were subjected to paired-end 
sequencing using Illumina MiSeq. Indels located 3-bp upstream of the 
PAM were considered to be the mutations induced by RGENs. 
6. Whole genome and digenome sequencing
Genomic DNA (1ug) was fragmented using the Covaris system 
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(Life Technologies) and polished to generate blunt ends using End 
Repair Mix. Fragmented DNA was ligated with adapters to produce 
libraries, which were then subjected to WGS using an Illumina HiSeq 
X Ten Sequencer at Macrogen. Indels were called by ISSAC software. 
7. Analysis of off-target effects at homologous sites
I used Cas-OFFinder (www.rgenome.net) to find potential 
off-target sites that differed from on-target sequences by up to 8 
nucleotides and that differed by up to 2 nucleotides with a 1-nt to 5-nt 
DNA or RNA bulge. Next, I obtained cigar string information around 
+/- 10 bp from potential cleavage sites in BAM files and derived the 
most common cigar strings. Next, I compared the most common cigar 
strings with wild-type sequences to identify candidate sites with indels. 
The computer program used in this study is available upon request. I 




A. Off-target analysis of clonal cells using whole 
genome sequencing (WGS)
1. Generation of mutant human haploid cells.
HAP1 is a human haploid cell which is generated by KBM7, a 
leukemia cell line (Carette et al., 2009). HAP1 is easy to make 
homologues Knockout, because this cell has only one copy for its 
chromosomes. I generated five kinds of KO HAP1 cell lines, each with 
a single disruption in a kinase gene (ABL1, EPHB2, ERBB3, FGFR2 
and FGFR4). RGEN mediated gene KO was confirmed by T7E1 assay 
and Sanger sequencing (Figure 1A, B). 
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Figure 1.
Figure 1. Generation of gene KO in HAP1 haploid cells (A) Gene 
knockout was confirmed in clonal populations of HAP1 haploid cells. 
WT, wild-type; MT, mutant; WT+MT, a 1:1 mixture of WT and MT 
PCR amplicons. (B) DNA sequences of wild-type and mutant clones. 
The PAM is shown in blue. Inserted bases are shown in red.
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2. Whole genome sequencing of human haploid cells
Genomic DNA isolated from these mutant HAP1 clones and 
wild-type HAP1 cells were subjected to WGS via Illumina HiSeq X. 
Wild-type and ABL1 KO HAP1 cells genomic DNAs were sequenced 
twice to check the WGS reproducibility. I used Isaac variant calling 
program (Raczy et al., 2013) to find RGEN-induced off-target indel 
genome widely (Figure 2). I used several bioinformatics filter to find 
off-target indel which is induced by RGEN (Table 1 and Figure 2). 
First, indels presented in the public database and heterozygous 
indels were discarded. Second, I compared each KO clone indels with 
other types of KO or wild-type indels, and overlap indels have 
removed to get each KO clone-specific indels. Third, I compared 
RGEN target sites with candidates, and less than 10 nucleotide 
mismatch with 5’-N(G/A)G-3’ PAM have been chosen for next step. 
Finally I got 9 to 84 indel sites contained a 5’-N(G/A)G-3’ PAM 
sequence and had at least 10 nucleotide matches with respective 
on-target sequences. Only one candidates validated by Sanger 
sequencing in ERBB3 KO clone, and this site was not present in the 
wild-type genome (Figure 3A). 
To determine whether validated indel was caused by an RGEN 
off-target effect, I delivered ERBB3 targeting Cas9 RGEN to HAPI 
cells. The indel was not detected in validated sites, so I conclude this 
site was induced by spontaneous mutation (Drake et al., 1998) which is 
acquired by cell culture (Figure 3B).  
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The Isaac variant calling program missed one of the five 
on-target mutation. This mutation consisted of a 12-bp deletion and a 
4-bp insertion at the target site (Figure 3C, D). This result show that 
the limitation of the variant calling algorithm.  
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Figure 2
Figure 2.  Analysis of off-target effects in gene KO clones via whole 
genome sequencing (WGS). Schematic workflow of off-target analysis 
of gene KO clones via WGS. 
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Figure 3. Analysis of off-target effects in gene KO clones via whole 
genome sequencing (WGS). (A) Off-target candidates with a small 
deletion in the ERBB3 KO clone which is confirmed by Sanger 
sequencing. (B) RGEN-mediated mutagenesis at the on-target and 
potential off-target sites. Mutation frequencies (%) were measured using 
T7E1 and targeted deep sequencing. (C) The on-target mutant sequence 
in the FGFR4 KO clone. The PAM sequence is shown in blue and 
inserted bases are shown in red. (D) Integrative Genomics Viewer 
(IGV) image at the FGFR4 on-target site.
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3. Examining potential off-target sites.
Sometime RGEN induce insertion and deletion together (Figure 
3D), which is hard to identified by variant calling algorithms. To solve 
this problem, I made computer program which generate the consensus 
sequence of on-/off-target sites using cigar string information (Figure 4). 
For that, I used Cas-OFFinder to import the list of potential off-target 
sites that differed from on-target sites by up to 8 nucleotides or that 
differed by 2 nucleotides with a DNA or RNA bulge (Figure 5A). I 
made consensus sequence of these potential off-target sites, and this 
program only identified on-target mutation (Figure 5B). These result 






Figure 4. Schematic of consensus sequence generation.
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Figure 5
Figure 5. Analysis of off-target effects in gene KO clones via 
consensus sequence generation. (A) The number of potential off-target 
sites that differ from on-target sites by up to 8 nucleotides or by 2 
nucleotides with a DNA or RNA bulge of up to 5 nucleotides in 
length. (B) On-target mutations in five KO clones identified by 
consensus sequence comparison.
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B. Digenome-seq for genome-wide RGEN off-target 
profiling.
1. Genomic DNA digestion using RGENs in vitro.
I next asked whether I could profile RGEN off-target mutation 
in a bulk population of cells. To answer this question, I subject RGEN 
mediate digested genomes to WGS. For genomic DNA digestion, I 
mixed genomic DNA with pre-incubated Cas9 and HBB gene-specific 
sgRNA complex at variable concentrations that ranged from 0.03 nM to 
300 nM. I next used quantitative PCR to examine DNA cleavage at 
these sites (Figure 6). In the HBB on-target and off-target 1 (OT1) 
sites, DNA was almost completely digested at a low RGEN 
concentration (0.03nM Cas9) (Figure 7A). However, the OT3 site was 
completely digested only at high RGEN concentration (Figure 7A). The 
other two sites, OT7 and OT12 were not digested even high RGEN 
concentration (Figure 7A). I next transfected this HBB targeting RGEN 
to HAP1 cells and mutation was detected by deep sequencing. HBB 
gene-specific RGEN induced high indel frequency at both on-target and 
OT1 sites (Figure 7B). OT3 site also detected mutation with a 
frequency of 4.3% (Figure 7B). The mutation of other two potential 
off-target sites, OT7 and OT12, were not detected using deep 
sequencing (detection limit, ~0.1%) (Figure 7B). 
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Figure 6




Figure 7.  RGEN-mediated genomic DNA digestion in vitro. (A) 
Fraction of intact genomic DNA not cleaved by the HBB-targeting 
RGEN at on-target and four potential off-target sites. For the 1X 
reaction, Cas9 protein (40ug, 300nM) and sgRNA (30ug, 900nM) were 
incubated with 8ug of HAP1 genomic DNA in a volume of 400 uL 
for 8 h. Both Cas9 and sgRNA were serially diluted by 10-fold to 
10,000-fold. The fraction of uncleaved DNA was measured by qPCR. 
(Bottom) DNA sequences of the on-target and the four potential 
off-target sites. Mismatched nucleotides are shown in red and the PAM 
sequence is shown in blue. (B) Measuring RGEN-driven mutation 
frequencies with the targeted deep sequencing at the on-target and 
potential off-target sites. 
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2. Nuclease-digested genomes sequencing (Digenome-seq) : 
Straight alignment vs. staggered alignment
Genomic DNA was purified from mock- and RGEN-transfected 
HAP1 cells before and after in vitro RGEN digestion at 300nM Cas9 
protein. These four different genomic DNAs were subjected to WGS to 
observe difference between non-digested and digested DNA (Figure 8). 
After aligning sequence reads into the reference genome, I observed 
sequence alignments pattern at the on-target and the four different 
homologous sites using Integrative Genomics Viewer (IGV). Digested 
DNA has unusual patterns of straight alignments at the on-target, OT1, 
and OT3 sites (Figure 9 and Figure 10A, B). OT 7 and OT12 sites, 
which are invalidated off-target sites, showed both straight and 
staggered alignments (Figure 10C, D). In contrast, I cannot detect 
unusual sequence alignment in non-digested DNA. I next compared the 
digested DNA from intact genome with RGEN-transfected genome. I 
could examine both straight and staggered alignments at on-target, OT1, 
and OT3 sites (Figure 9 and Figure 10A, B). RGEN-mediated mutant 
sequence was not cleaved by in vitro RGEN treatments, so these 
mutant sequences induce staggered alignments.
These results suggest that Digenome-Seq is sensitive enough to 
allow identification of rare off-target mutations and that a straight or 
vertical alignment of sequence reads is a unique signature of RGEN 
cleavage in vitro, although not all sites with straight alignments are 
bona fide off-target sites.
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Figure 8
Figure 8. RGEN-induced digenome sequencing to profiling off-target 
sites. Schematic overview of nuclease-digested whole genome 
sequencing for the identification of off-target sites. Genomic DNA 
isolated from mock-transfected or RGEN-transfected cells is digested by 
the RGEN, and subjected to WGS. Sequence reads are aligned to the 
reference genome (hg19) and visualized using the IGV program. 
Forward and reverse sequence reads are shown in pink and blue, 
respectively. Red triangles and vertical lines indicate cleavage positions. 
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Figure 9
Figure 9. Representative IGV images obtained using the HBB-specific 
RGEN at the on-target site. 
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Figure 10
Figure 10. RGEN-induced Digenome sequencing to capture off-target 
sites. (A-D) Representative IGV images obtained using the HBB-specific 
RGEN at the potential off-target sites OT1 (A), OT3 (B), OT7 (C), 
and OT12 (D). 
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3. 5’ End plot at single nucleotide resolution
To identify potential RGEN off-target sites on a genomic scale, 
I need to develop a computer program that searches for straight 
alignments of sequence reads. First, I plotted the count of sequence 
reads whose 5’ ends started at the nucleotide position near the HBB 
on-target and two validated off-target sites at single nucleotide 
resolution (Figure 11A, B). Because both Watson and Crick strands 
were sequenced, I assumed that almost an equal number of sequence 
reads, corresponding to either the Watson or Crick strand, should be 
observed right next to each other at a cleavage site, producing double 
peaks. As expected, the digenome gave rise to double peaks at the 
three cleavage sites (Figure 11B). The intact genome that had not 
undergone RGEN treatment did not detected such double-peak patterns 
at these sites (Figure 11B). 
Next, I computationally searched for sites where the count of 
sequence reads with the same 5’ end was greater than 10 in both 
strands and where at least 20% of sequence reads were aligned 
vertically in mock-transfected digenome and two different concentration 




Figure 11. RGEN-induced Digenome sequencing to capture off-target 
sites. (A) 5’ End plots showing the absolute and relative number of 
sequence reads with the same 5’ end across nucleotide positions in 
OT1 and OT3 region. (B) 5’ End plots showing the absolute and 
relative number of sequence reads with the same 5’ end across 
nucleotide positions at on-target site. 
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A total of 17 and 78 sites, including the on-target and two 
validated off-target sites, were identified in the mock-transfected 
digenome treated with 3 nM and 300 nM RGEN, respectively, which 
showed double-peak patterns in a 5’ end plot and straight alignments in 
an IGV image (Figure 12A). Among these sites, one and two sites in 
the digenomes treated with 3 nM and 300 nM RGEN, respectively, 
were false positives that resulted from naturally-occurring indels (Figure 
13A-C). Such patterns were observed at 125 sites, including the three 
validated on- and off-target sites in the RGEN-transfected digenome 
(Figure 12A). Importantly, the two invalidated OT7 and OT12 sites did 
not show double-peak patterns in these three digenomes. Most sites 
were commonly identified in the three digenomes, demonstrating the 
high reproducibility of Digenome-Seq. Thus, 15 (94%) of the 16 
candidate sites (excluding the one false positive site) found in the 
mock-transfected digenome (3 nM RGEN) were also identified in the 
other two independent digenomes. 74 (97%) of 76 candidate sites found 
in the mock-transfected digenome (300 nM) were also identified in the 
RGEN-transfected digenome (Figure 12A). I compared DNA sequences 
at the 74 common sites identified in the RGEN-transfected and 
mock-transfected digenomes with the 20-bp on-target site and found that 
of the 20 nucleotides, all but the one at the 5’ end were conserved 
(Figure 12B). Furthermore, the sequence logo or de novo motif 
computationally obtained by comparing the DNA sequences at the 74 
sites with one another rather than with the on-target sequence clearly 
showed matches with the on-target sequence at all positions other than 
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the first two nucleotides (Figure 12B, C). I also found that the fewer 
mismatches there were in homologous sites, the more likely they were 
to be captured by Digenome-Seq. Thus, 7 out of 15 (47%) and 14 out 
of 142 (10%) homologous sites that differed by 3 and 4 nucleotides, 
respectively, from the on-target site were captured, but only 15 out of 
1,191 sites (1.2%) and one out of 7,896 sites (0.013%) that differed by 
5 and 6 nucleotides, respectively, were captured (Figure 12D). Taken 
together, these results indicate that most of the double-peak patterns are 
caused by RGEN digestion in vitro and that Digenome-Seq can capture 




Table2. Digenome-captured HBB off-target candidate sites.
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Figure 12
Figure 12. Off-target sites of the HBB RGEN captured by 
Digestome-Seq. (A) Venn diagram showing the number of 
Digenome-captured sites using the HBB RGEN in mock-transfected or 
RGEN-transfected cells. (B) Heatmap comparing digestome-captured sites 
with the on-target site. Dark red and dark blue correspond to 100% 
and 0% matches, respectively, at a given position. (C) Sequence logo 
obtained via WebLogo using DNA sequences at digestome-captured 




Figure 13. False-positive positions captured in the intact genome 
sequences. (A-C) Representative IGV images around false-positive sites 
that resulted from naturally-occurring indels in HAP1 cells. 
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4. Deep sequencing to confirm off-target effects at candidate sites
I performed deep sequencing to validate or invalidate off-target 
effects at the 74 common sites identified in the two independent 
digenomes (Figure 12D). In addition, I also tested the other 8 sites that 
differed from the on-target site by three nucleotides but were not 
captured by Digenome-Seq. No off-target indels were detected at these 
8 sites with a frequency of at least 0.1% and greater than that of 
negative control (Fisher exact test, p < 0.01) (Figure 12D). Indels were 
observed at 5 sites including already-validated on-target, OT1, and OT3 
sites, among the 74 sites, with frequencies ranging from 0.11% to 87% 
(Figure 14A). At the other two newly-validated off-target sites, termed 
HBB_48 and HBB_75, indels were detected with a frequency of 0.11% 
and 2.2%, respectively (Figure 14B, C). These two sites differed from 
the on-target site by three nucleotides. These results show that 
Digenome-Seq is a sensitive and reproducible method to profile 




Figure 14. Off-target sites of the HBB RGEN validated by targeted 
deep sequencing. (A) Off-target sites validated by targeted deep 
sequencing. Blue and red bars represent indel frequencies obtained using 
mock-transfected HAP1 cells and the HBB RGEN-transfected HAP1 
cells, respectively. (Left) DNA sequences of on-target and off-target 
sites. Mismatched bases are shown in red. The PAM is shown in blue. 
(Right). (B-C) Examples of deep sequencing result of new validated 
HBB off-target region. Inserted nucleotides are shown in red and the 
PAM sequence is shown in blue.
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5. Digenome sequencing with another ‘promiscuous’ RGEN
I performed Digenome-Seq with another RGEN that had been 
shown to induce on-target mutations at a VEGF-A locus and off-target 
mutations at four homologous sites. A total of 81 sites, including the 
on-target and four validated off-target sites, were captured that showed 
double-peak patterns (Figure 15A). All of the DNA sequences at these 
81 sites contained the canonical 5’-NGG-3’ PAM. Comparison of these 
sequences with the on-target sequence showed matches at every 
nucleotide position (Figure 15B). I also compared these sequences with 
one another to obtain a de novo motif: The resulting sequence logo 
also showed matches with the target sequence at almost every 
nucleotide position, suggesting that each nucleotide in the 20-nt sgRNA 
sequence contributed to the specificity (Figure 15B, C). I then used 
targeted deep sequencing to confirm on-target and off-target effects at 
the 81 sites captured by digenome analysis and 28 sites that differed 
by 3 or fewer nucleotides from the on-target site but were not captured 
by Digenome-Seq (Figure 15D). This RGEN was highly active in 
HAP1 cells, producing indels at the target site with a frequency of 
87% and at the four previously-validated off-target sites with 
frequencies that ranged from 0.32% to 79%. In addition, four new 
off-target sites were identified at which indels were induced with 
frequencies that ranged from 0.065% to 6.4% (Figure 16A-E). The 
indel frequency at each of these sites obtained using the RGEN was 
significantly greater than that obtained using an empty vector control 
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(Fisher exact test, p < 0.01). These off-target sites contained one to six 
nucleotide mismatches with the 20-nt target sequence and at least one 
mismatch in the PAM-proximal seed region. There are 13,892 sites 
with 6-nt mismatches in the human genome but only 6 sites (0.043%) 
were captured by digenome sequencing and, among them, only one site 
was validated by deep sequencing (Figure 15D). To the best of our 
knowledge, an RGEN off-target site with 6-nt mismatches had never 
previously been identified. None of these validated off-target sites 
contained a DNA or RNA bulge, although 40 out of 81 sites captured 
by Digesome-Seq contained a missing or extra nucleotide compared to 
the 20-nt target sequence. At all the other sites, including those not 
captured by Digesome-Seq, indel frequencies obtained using the RGEN 
were below 0.05% or were smaller than or not statistically different 





Table3. Digenome-captured VEGFA off-target candidate sites.
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Figure 15
Figure 15. Off-target sites of the VEGF-A RGEN captured by 
Digenome-seq. (A) 5’ End plots at the one of VEGF-A off-target site. 
(B) Heatmap comparing digenome-captured sites with the on-target site. 
Dark red and dark blue correspond to 100% and 0% matches, 
respectively, at a given position. (C) Sequence logo obtained via 
WebLogo using DNA sequences at digenome-captured sites. (D) 




Figure 16. Validation of off-target sites captured by Digenome-seq using 
VEGFA targeting RGEN. (A) Off-target sites validated by targeted deep 
sequencing. Blue and red bars represent indel frequencies obtained using 
mock-transfected HAP1 cells and the VEGF-A RGEN-transfected HAP1 
cells, respectively. (Left) DNA sequences of on-target and off-target 
sites. Mismatched bases are shown in red. The PAM is shown in blue. 
(B-E) New validated Off-target sites were detected by targeted deep 
sequencing. Inserted nucleotides are shown in red and the PAM 
sequence is shown in blue.
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6. Avoiding RGEN off-target effects via modified sgRNAs
sgRNAs with two extra guanine nucleotides at the 5’ terminus 
(termed ggX20 sgRNAs) can efficiently discriminate on-target sites from 
homologous sites that differ by two or more nucleotides, reducing 
off-target effects by orders of magnitude without sacrificing on-target 
effects. I replaced the two ‘promiscuous’ gX19 (HBB) and GX19 
(VEGF-A) sgRNAs with respective ggX20 sgRNAs (‘g’ and ‘G’ 
represent a mismatched guanine and matched guanine, respectively.) 
(Figure 17A) and measured on-target and off-target mutation frequencies 
in HAP1 and K562 cells at the sites identified by Digesome-Seq and 
validated by targeted deep sequencing. Strikingly, indels were barely 
detectable above noise levels (i.e. deep sequencing error) at the several 
validated off-target sites in the two genes when I used the ggX20 
sgRNAs (Figure 17B-E). In contrast, these sgRNAs were almost equally 
active, compared to the gX19 and GX19 sgRNAs, at the respective 
on-target sites in HAP1 cells, although they were less active than the 
two conventional sgRNAs at the target sites in K562 cells. Based on 
the specificity ratio of on- to off-target indel frequencies, the two 
modified sgRNAs showed up to 660-fold greater specificity than the 






Figure 17. Comparison of conventional sgRNAs with modified sgRNAs 
that include two extra guanine nucleotides. (A) Schematic of gX19 
sgRNA, GX19 sgRNA, and ggX20 sgRNA. (B and C) Indel 
frequencies at the HBB on-target and the four validated off-target sites 
in HAP1 cells (B) and K562 cells (C) were measured via targeted deep 
sequencing. N.A., not applicable when indel frequencies with RGENs 
were lower than those with negative control. P value was calculated by 
Fisher exact test. (D and E) Indel frequencies at the VEGF-A on-target 
and the eight validated off-target sites in HAP1 cells (D) and K562 
cells (E) were measured via targeted deep sequencing. 
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Table 4. 
Table 4. Comparison specificity ratio of conventional sgRNAs with 
modified sgRNAs. Specificity ratio calculated by dividing indel 
frequencies at the on-target site with those at an off-target site in HBB  
and VEGF-A.
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C. Multiplex Digenome-seq for genome-wide target 
specificities of RGEN 
1. Improving Digenome-seq
First, I developed a scoring system to computationally identify 
in vitro cleavage sites across the human genome using WGS data. 
Although our original Digenome-seq analysis was highly reproducible, 
some sites with heterogeneous cleavage patterns or with a low 
sequencing depth were often missed. I found that these sites could be 
identified by assuming that Cas9 can produce one or two-nucleotide 
overhangs in addition to blunt ends. I assigned a DNA cleavage score 
to each nt position, based on patterns of alignments of sequence reads 
(Figure 18). This improved program successfully captured many 
additional sites that had been missed previously. A genome-wide plot of 
cleavage scores showed that false-positive sites obtained with undigested 
genomic DNA were still extremely rare (Figure 19): A few 
false-positive sites identified in the entire genome contained 
naturally-occurring indels in the genomic DNA and could be filtered 
out with ease.
I also found that sgRNAs transcribed using a plasmid template 
in a Digenome-seq analysis did not cleave any of the false-positive, 
bulge-type off-target sites, with a missing nucleotide (nt) compared to 
the on-target site (Lin et al., 2014), which were captured with those 
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transcribed using an oligonucleotide duplex (Figure 20A). Apparently, 
the latter sgRNAs were heterogeneous, containing truncated molecules 
transcribed from synthesis-failed oligonucleotides. As a result, cleavage 
sites identified using sgRNAs transcribed from a plasmid template were 
more highly homologous to its on-target site than those identified using 
sgRNAs transcribed from an oligonucleotide template, as shown by 
sequence logos obtained computationally by comparing DNA sequences 
around cleavage sites with each other (Figure 20B). Thus, the use of a 
new cleavage scoring system and sgRNAs transcribed from plasmid 
templates substantially reduced the number of false-negative sites and 




Figure 18. in vitro DNA cleavage scoring system for Digenome-seq 
analysis. I assigned a DNA cleavage score to each nucleotide position 
across the human genome using the following equation and set a cutoff 
value of 2.5 to identify in vitro DNA cleavage sites. 
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Figure 19.
Figure 19. Scoring system of Digenome-seq analysis. Genome-wide 
Circos plots of in vitro DNA cleavage scores. Human genomic DNA 





Figure 20. Comparison of Digenome-seq using sgRNA transcribed from 
an oligonucleotide duplex or a plasmid. (A) Schematic overview of 
Digenome-seq using sgRNA transcribed from an oligonucleotide duplex 
or a plasmid. (B-C) Sequence logos obtained using sgRNA transcribed 
from an oligonucleotide duplex (B) or a plasmid (C). 
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2. Multiplex Digenome-seq
Unlike other methods, Digenome-seq can be multiplexed 
without increasing sequencing depth proportionally to the number of 
nucleases. I chose 10 sgRNAs that had been analyzed individually 
using GUIDE-seq (Tsai et al., 2015), which is likely to be more 
sensitive than IDLV capture and other methods. I digested human 
genomic DNA with a mixture of the Cas9 protein, the 10 sgRNAs, and 
one additional sgRNA targeted to the HBB gene, which I had analyzed 
in our previous study (Kim et al., 2015), and carried out two 
independent WGS analyses (Figure 21). Genome-wide in vitro cleavage 
sites were identified computationally using the scoring system. A total 
of 964 sites were found in the human genome. All of these sites were 
then classified computationally according to the edit distance from the 
on-target sites (Figure 21).
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Figure 21.
Figure 21. Multiplex Digenome-seq. Schematic overview of multiplex 
Digenome-seq. 
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First, I checked whether an sgRNA in a pool can cleave its 
on-target and off-target sites. 17 out of 30 (= 57%) sites that were 
cleaved using the single HBB-specific sgRNA alone at high 
concentration (900 nM) plus Cas9 (300 nM) were also captured by 
multiplex Digenome-seq using the same sgRNA at low concentration 
(82 nM) (Figure 22A and B). Note that more sites are captured at 
higher concentration of sgRNAs. Importantly, all the four off-target sites 
as well as the on-target site that had been validated using targeted deep 
sequencing in our previous study were identified by multiplex 
Digenome-seq. This result suggests that each sgRNA in a pool of up to 
11 sgRNs can guide Cas9 to most of its on-target and off-target sites 
independently from each other, supporting the basis of multiplexing.
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Figure 22.
Figure 22. Multiplex Digenome-seq. (A) A Venn diagram showing the 
number of in vitro cleavage sites captured by monoplex and muliplex 
Digenom-seq analyses. (B) in vitro DNA cleavage scores across 
Chromosome X obtained by monoplex or multiplex digenome seq. 
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3. In vitro cleavage sites
The 11 sgRNAs showed a wide spectrum of genome-wide 
specificities : Then umber of cleavage sites per sgRNA in the human 
genome ranged from 13 to 302 (Figure 23). As expected, all of the 11 
on-target sites and most of the sites with 1 or 2 mismatches, identified 
in the human genome using Cas-OFFinder (Bae et al., 2014), were 
captured by Digenome-seq (Figure 24A). However, sites with more than 
3 mismatches were rarely captured. The fraction of Digenome-captured 
sites decreased exponentially as the number of mismatches increased 
from 3 to 6 (Figure 24A). I also found that sites with 2 or more 
mismatches in the seed region were much less likely to be cleaved in 
vitro than those with 0 or 1 mismatch in the seed (P < 0.01, Student’s 
t-test) (Figure 24B).
Interestingly, I found a strong correlation (R2=0.93) between the 
number of Digenome-captured sites and the number of homologous sites 
with 6 or fewer nt mismatches in the human genome (Figure 24C). 
The 6 sgRNAs with fewer than 13,000 such homologous sites in the 
human genome were much more specific (P < 0.01, Student’s t-test), 
cleaving 46 or fewer sites in vitro (28 sites/sgRNA, on average), than 
the other 5 sgRNAs with more than 16,000 such sites, cleaving 63 or 
more sites in vitro (161 sites/sgRNA, on average) (Figure 24C and D). 
This result is seemingly in contrast with the poor correlation (R2=0.29) 
observed between the number of GUIDE-seq positive sites and the 
orthogonality of the target site relative to the human genome (Figure 
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25A) (Tsai et al., 2015). The VEGFA 2 site was an outlier, at least 
partially causing the poor correlation. I noted, however, that the 5 most 
specific sgRNAs revealed by GUIDE-seq, cleaving 10 or fewer sites in 
cells, were coincident with the most specific sgRNAs revealed by 
Digenome-seq.   
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Figure 23.
Figure 23. Comparison of the Digenome-seq, GUIDE-seq, and HTGTS. 
Venn diagrams showing the number of sites captured by Digenome-seq, 
GUIDE-seq, and HTGTS. 
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Figure 24.
Figure 24. Analysis of multiplex Digenome-captured sites. (A-B) 
Fractions of sites captured by Digenome-seq according to the total 
mismatch number (A) and the mismatch number in the seed region (B). 
(C-D) Scatterplot of the number of sites with 6 or fewer mismatches in 
the human genome vs. the number of Digenome-captured sites (top). 11 
RGEN target sites were divided into two groups, G1 and G2 (those 
with fewer than 13,000 and 16,000 sites, respectively, harboring 6 or 
fewer mismatches in the human genome) (bottom). Error bars represent 
SEM. The P value was calculated by Student’s t-test.
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Figure 25.
Figure 25. Comparison of the Digenome-seq and GUIDE-seq. (A) Poor 
correlation between the number of GUIDE-seq positive sites and the 
number of homologous sites with 6 or fewer mismatches in the human 
genome. (B) Scatterplot of the number of GUIDE-captured sites vs. the 
number of Digenome-captured sites. 
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4. Digenome-seq vs. other methods
On average, multiplex Digenome-seq successfully identified 
80.8% of sites captured previously by GUIDE-seq (Figure 23). For 
example, all of the GUIDE-captured sites using the three sgRNAs 
specific to the VEGFA 1, RNF2, and HEK293-3 sites were identified 
by Digenome-seq. In addition, multiplex Digenome-seq captured a total 
of 703 new sites (70 sites per sgRNA, on average) that had been 
missed by GUIDE-seq (Figure 23). As a result, GUIDE-seq had 
captured 25.6% of sites identified by multiplex Digenome-seq. The 
RNF2-specific sgRNA was a striking example. Two independent 
GUIDE-seq analyses had failed to capture any single off-target site, 
whereas Digenome-seq identified 12 cleavage sites in addition to the 
on-target site. In fact, I observed a poor correlation (R2 = 0.20) 
between the number of Digenome-positive sites and that of 
GUIDE-positive sites (Figure 25B). It is likely that many additional 
sites those are cleaved in vitro and, thereby, captured by Digenome-seq 
are not accessible in cells, owing to chromatin.  
Digenome-seq yielded more candidate off-target sites than 
GUIDE-seq for 9 out of 10 sgRNAs, but still was not comprehensive. 
(The HBB sgRNA had not been analyzed by GUIDE-seq.) Thus, in 
aggregate, GUIDE-seq had captured a total of 168 sites that were 
missed by Digenome-seq. Two sgRNAs targeted to the VEGFA 1 and 
EMX1 sites had also been analyzed by HTGTS (Figure 23). Most of 
sites (31 out of 40 sites for VEGFA 1 and 17 out of 19 sites for 
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EMX1) captured by at least one of the other two methods were also 
identified by Digenome-seq, but it missed 9 and 2 sites, respectively. It 
is possible that some of these sites were false positives that resulted 
from PCR primer-dependent artifacts or naturally-occurring DSBs, 
intrinsic limitations of GUIDE-seq and HTGTS. Many of these sites, 
especially the two EMX1 off-target sites commonly identified by the 
other two methods, however, would have been missed by multiplex 
Digenome-seq, owing to a low sequencing depth at these particular sites 
(Figure 26) or the low concentration (82 nM) of the sgRNA. These 
problems could be alleviated by performing WGS at a higher 




Figure 26. Two EMX1 off-target sites captured by HTGTS and 
GUIDE-seq but missed by Digenome-seq. The two numbers below the 
IGV images indicate DNA cleavage scores calculated using the equation 
in Fig. 15, which are smaller than the cutoff value of 2.5.
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The VEGFA 2-specific sgRNA was the only exception to the 
rule that Digenome-seq captures more candidate sites than GUIDE-seq. 
Thus, GUIDE-seq had identified 122 sites that were missed by 
Digenome-seq. The target sequence was unusual, consisting of a stretch 
of cytosines. Many sequence reads, obtained by WGS, at homopolymer 
sites can be discarded by a mapping program. GUIDE-seq may still 
capture these sites because PCR is used to amplify 
oligonucleotide-captured sites. 
I also compared cleavage sites identified in this study with 
those captured by chromatin immunoprecipitation sequencing (ChiP-seq) 
using catalytically dead Cas9 (dCas9) (Kuscu et al., 2014). Strikingly, a 
vast majority of Cas9-cleaved sites (288 sites, 98%) identified by 
Digenome-seq were not bound by dCas9 (Figure 27). This result 
suggests that DNA binding by Cas9 is uncoupled from DNA cleavage 
and that ChiP-seq using dCas9 is inappropriate for assessing 
genome-wide specificities of Cas9 RGENs, although it may still be 
useful for profiling the specificities of dCas9-based transcription factors 
and epigenome regulators (Tsai et al., 2015).
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Figure 27.
Figure 27. Comparison of the Digenome-seq and CHIP-seq. Venn 
diagrams showing the number of sites captured by Digenome-seq and 
CHIP-seq in HEK293-1(A), -2(B), -3(C), and -4(D) site.
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Next, I compared Digenome-seq with direct in situ breaks labeling, 
enrichment on streptavidin and next-generation sequencing (BLESS) 
(Ran et al., 2015). Majority of BLESS captured sites were not 
identified by Digenome-seq and sequence logo ,which is captured in 
only BLESS, showing any similarity with on-target sequence (Figure 




Figure 28. Comparison of the Digenome-seq and Bless. (A-B) Venn 
diagrams showing the number of sites captured by Digenome-seq and 
Bless. Sequence logos obtained using Digenome-seq only  captured 
sites, commonly identified by the two methods, and Bless only captured 
sites.
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5. Validation of off-target sites in cells
I then investigated, using a next-generation sequencing (NGS) 
platform, whether each sgRNA plus Cas9 could induce off-target indels 
in HeLa cells at some of these Digenome-captured and GUIDE-captured 
sites (Table 5). I chose candidate off-target sites with a fewer 
mismatches, irrespective of DNA cleavage scores in this analysis. Indels 
were detected over background noise levels caused by sequencing errors 
at 116 out of 132 (=88%) sites commonly captured using Digenome-seq 
and GUIDE-seq. In contrast, many of the sites captured by 
Digenome-seq alone and GUIDE-seq alone were not validated by 
targeted deep sequencing. Indels were induced above noise levels at 21 
out of 127 (= 17%) sites captured by Digenome-seq alone and at 23 
out of 45 (= 51%) sites captured by GUIDE-seq alone, confirming that 
neither of the two methods was comprehensive. Thus, the overall 
validation rate was 53% [= (21 + 116)/(127 + 132)] with 




Table 5. Validation of off-target sites in human cells using 
next-generation sequencing (NGS). Indel frequencies at off-target sites 
captured by Digenome-seq and GUIDE-seq were measured in human 
cells. Validated off-target sites were those with indel frequencies above 
noise indel frequencies obtained in the absence of RGEN transfection. 
“Digenome only” and “GUIDE only” sites exclude “Digenome and 
GUIDE” sites that were commonly identified by the two methods.
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Indel frequencies at most of these validated sites were below 
1%, much lower than those at respective on-target sites. For example, 
the RNF2-targeted sgRNA induced indels at the on-target site and two 
off-target sites identified in this study with a frequency of 68%, 0.25%, 
and 0.09%, respectively (Figure 29). It still is possible that indels could 
be induced at NGS-invalidated sites with frequencies below noise levels 
(0.001% to 4%, depending on the site).
To reduce off-target effects, I replaced sgRNAs with versions 
containing two extra guanines at the 5’ terminus (termed ggX20 
sgRNAs) (Cho et al., 2014) (Figure 30A). These modified sgRNAs 
were more specific than their respective GX19 sgRNAs by up to 598 
fold (Figure 30B-D and Figure 31). It is of note that off-target indels 
were not detected above noise levels with the RNF2-specific ggX20 




Figure 29. Indel frequencies (log scale) at on-target and off-target sites 
determined in HeLa cells transfected with the RNF2-specific sgRNA.
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Figure 30.
Figure 30. Indel frequencies determined using targeted deep sequencing 
at off-target sites. (A) Schematic of conventional sgRNAs (gX19 
sgRNA) and modified sgRNAs (ggX20 sgRNA). Indel frequencies at 
NGS-validated on- and off-target sites for the EMX1 (B), HEK293-3 
(C), and RNF2 sgRNAs (D). 
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Figure 31.
Figure 31. Comparison specificity ratio of conventional sgRNAs with 
modified sgRNAs. Specificity ratio calculated by dividing indel 
frequencies at the on-target site with those at an off-target site in 
EMX1, HEK293-3  and RNF2.
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D. Generation of RGEN targetable sites prediction program
To disrupt a gene of interest using RGENs, one should choose 
target sites with no or few off-target effects. First, a desired target site 
should have only a few or no off-target sites in the genome. Second, 
indel frequencies at these off-target sites should be much lower than 
the frequency at the on-target site. Our results suggest that a unique 
site that has fewer than 13,000 homologous sites with up to 6 
mismatches in the human genome and that has no homologous sites 
with up to 2 mismatches is desirable to minimize off-target effects. Out 
of 1715 targetable sites containing the 5’-NGG-3’ PAM in the four 
genes examined in this study, 368 (= 21.5%) sites satisfy these criteria 
(Table 6). In addition, I present an off-target score (Table 7) that 
accounts for numbers of potential off-target sites in the genome, 
fractions of these sites captured by Digenome-seq (Figure 24B), and 
median indel frequencies at these sites (Figure 33). One should choose 
a low-score site to avoid or reduce off-target effects. A web-based 
computer program that shows off-target scores in a gene of interest will 








Figure 32. Analysis of NGS-validated and -invalidated off-target sites. 
Plots of relative indel frequencies (log scale) at off-target sites 
harboring the number of mismatches indicated in the entire 20-nt 
sequence (A) or the 10-nt seed sequence (B and C). NGS-tested sites 
(A) were divided into two groups, validated sites (B) and invalidated 
sites (C). NGS-validated sites and NGS-invalidated sites were those 
with indel frequencies above and below, respectively, noise indel levels. 
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Table 7.
Table 7. Calculation of an off-target score assigned to the EMX1 target 




Figure 33. Off-target score calculator. (A) Overview of Off-target score 
calculator. (B) Example of off-target score calculator result.
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E. Generation of RGEN potential off-target sites prediction 
program based on Digenome-seq.
1. In vitro cleavage of genomic DNA
To make a potential off-target sites prediction program, I did 
digenome-seq using 100-types of sgRNA which targeting different gene 
(Figure 34A). First, I cloning the plasmid DNA which can express 
sgRNA by T7 promoter. Second each sgRNAs were expressed by in 
vitro transcription. Third cell-free genomic DNA was mixed with 
100-types of sgRNA/Cas9 protein complex and subjected to WGS. 
After alignment of sequencing data to hg19 reference genome, 




Figure 34. Multiplex Digenome-seq using 100-type sgRNA. (A) 
Overview of Multiplex Digenome-seq via 100-type sgRNA and Cas9 
protein. (B) Representative IGV images obtained using the Multiplex 
Digenome-seq at HBB and VEGFA1 on-/off-target site. 
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2. Generation of RGEN potential off-target sites prediction 
program
To make software program, I checked the cleavage of potential 
off-target sites which had one to six mismatch with on-target sites and 
I divided these sites to cleavage sites and non-cleavage sites. I made 
off-target prediction program using machine learning by finding the 
difference character between cleavage site and non-cleavage sites (Figure 
35).  Using these computer program, It is possible to predict potential 
off-target sites (Table 8).
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Figure 35.
Figure 35. Making of RGEN potential off-target sites prediction 




Table 8. Off-target sites predictor. Example of off-target predictor result.
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IV. Discussion
The genome-wide target specificity of CRISPR-Cas9 system is 
a broad interest in the genome-editing field. Prior studies have 
documented the CRISPR-Cas9 off-target effects via bioinformatics 
prediction based on sequence homology, mismatched guide RNA 
libraries, in vitro selection, reporter assays, and ChIP-seq. However, 
these studies have either been computationally determined by homology 
sites or have focused on CRISPR-Cas9 binding affinity. In this study, I 
have used Digenome-seq for genome-wide target cleavage specificity of 
CRISPR-Cas9 system in an unbiased manner. 
Several studies have been suggested to profiling genome-wide 
off-target effects of engineered nucleases in an unbiased manner. 
SELEX (systematic evolution of ligands by exponential enrichment) and 
chromatin immunoprecipitation–sequencing have been used to 
genome-wide screening of engineered nucleases (Gabriel et al., 2011; 
Kuscu et al., 2014; Wu et al., 2014), but these methods rely on DNA 
binding rather than DNA cleavage. Unfortunately, most DNA binding 
sites are not coupled with DNA cleavage sites (Figure 27). 
Integrase-defective lentiviral vector (IDLV) capture and in vitro selection 
are two different methods that detect nuclease cleavage sites rather than 
binding sites (Fu et al., 2014; Wang et al., 2015). However IDLV 
capture loss several known off-target sites and in vitro selection uses 
biased DNA substrate library that consists of >1012 variants. Veryr 
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ecently, two groupsr eported methods,t ermed HTGTS (High-throughput 
genome-wide translocation sequencing) (Frock et al., 2015), GUIDE-seq 
(Tsai et al., 2015), and Bless (Direct in situ breaks labeling, enrichment 
on streptavidin and next-generation sequencing) (Ran et al., 2015), of 
capturing double-strand breaks (DSBs) induced by Cas9 in cells. 
However these methods had high background levels because of many 
DSB which was arisen in cellular DNA. 
I found that the number of off-target candidates are 
comfortable depend on sgRNA in the range of 13 to 316. These 
finding is consistent with other genome-wide off-target profiling such as 
GUIDE-seq (Tsai et al., 2015). Therefore it is important to choose 
target sites with few off-target effects. Based on 11 kinds of 
digenome-seq and NGS validation result, I made program to predict 
off-target effect of target sites (Figure 31). It is believed that this 
program will eventually be capable of finding less off-target RGEN for 
therapeutic use.
To minimize or avoid off-target effects is a crucial issue for 
therapeutic use of RGEN. Several methods such as dimeric Cas9 
systems (paired Cas9 nickases (Cho et al., 2014; Mali et al., 2013a; 
Ran et al., 2013) and dCas9-FokI (Guilinger et al., 2014; Tsai et al., 
2014)), delivery of RGEN ribonucleoproteins (RNPs) (Kim et al., 2014; 
Ramakrishna et al., 2014; Zuris et al., 2015), and modified guide RNAs 
(Cho et al., 2014; Fu et al., 2014) have been published to reduce 
RGEN off-target effects. Recently two dependent group published that 
Cas9 protein modification can help to enhance RGEN specificity. In 
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this study, I used modified guide RNAs to ggX20 sgRNA (additional 
two extra guanine satthe 5’ terminus) to reduce off-target effects. I 
found that sgRNA modification could increase RGEN specificity up to 
598 fold. These sgRNA or Cas9 modifications will help to make 
specific use of RGEN.  
In the early RGEN off-target research, serval paper published 
that SpCas9 have high off-target mutagenesis effects in cells(Cradick et 
al., 2013;Fu et al., 2013;Hsu et al., 2013;Lin et al., 2014;Pattanayak et 
al., 2013). These papers finds potential off-target sites using in silico 
prediction based on similarity to the intended target site and mentioned 
that SpCas9 off-target cleavage sites have been detected up to five 
mismatches relative to the intended target sequence. However these 
papers choose ‘promiscuous’ RGEN, which had many similar sequences 
in the genome and these ‘promiscuous’ RGEN also had less that ten 
validated off-target in the whole genome with low mutagenesis level 
(Figure 15, 16). These validated off-target sites can be reduced by 
sgRNA modification. These result mentioned SpCas9 had somehow 
off-target sites and these off-target sites can be reduced by sgRNA or 
Cas9 modification.
In conclusion, Digenome-seq enables genome-wide off-target 
profiling of CRISPR-Cas9 system and this method also allow 
genome-wide profiling of other artificial nuclease such as ZFN, 
TALEN, Meganuclease, and Cpf1(Zetsche et al., 2015). Before use in a 
gene or cell therapy application, off-target effect should be monitored 
by Digesome-Seq to avoid oncogenic mutations and unwanted mutations 
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in essential genes. This method will also provide a litmus test in the 
development of next generation genome editing tools. 
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크리스퍼 유전자가위는 인간 세포를 비롯한 다양한 동식물
의 유전체 교정에 사용되어 왔지만, 인간 DNA 전체에 대한 정확성
을 측정할 수 있는 방법이 없었다. 이를 해결하기 위해 인간 DNA를
크리스퍼 유전자 가위로 처리한 후 전유전체 시퀀싱(Whole genome 
sequencing)을 통해 표적 염기서열(On-target)과 비표적 염기서열
(Off-target)을 찾는 방법인 절단 유전체 시퀀싱(Digenome-seq)을 개발
하였다. 절단 유전체 시퀀싱을 이용하여 찾아낸 비표적 염기서열이
실제 세포내에서도 작동하는 것을 확인 하였으며, 크리스퍼 유전자
가위를 구성하는 가이드 RNA의 말단에 구아닌 염기를 추가함으로
서 비표적위치에는 작동하지 않고 인간 유전체에서 단 한군데에만
작용하는 정교한 유전자가위를 만드는데 성공하였다. 이 실험결과를
통해 크리스퍼 유전자가위가 기존에 알려진 것과는 달리 매우 정교
하다는 사실을 보고하였다.
새롭게 만든 절단 유전체 시퀀싱 방법을 응용하여 한번에
10개 이상의 크리스퍼 유전자 가위의 오프타깃을 예측할 수 있는
Multiplex Digenome-seq 방법을 개발하였다. 또한, Multiplex 
Digenome-seq의 결과를 이용하여 비표적위치가 적은 크리스퍼 유전
자 가위를 예측할 수 있는 프로그램과 크리스퍼 유전자 가위의 비
표적 위치를 예측할 수 있는 프로그램을 만들었다. 이러한 기술을
이용하면 치료 목적으로 크리스퍼 유전자 가위를 사용하게 될 때, 
정교한 유전자 가위를 찾거나 특정 크리스퍼 유전자 가위의 비표적
위치를 예측하여 부작용을 없애는 데에 큰 도움이 될 것이다.  
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